CAS 1346547-00-9

Fórmula: C20H19FN4O2S

InChI: InChI=1S/C20H19FN4O2S/c1-20(2,3)28(26,27)13-5-7-16-14(11-13)17(8-9-22-16)23-19-15-10-12(21)4-6-18(15)24-25-19/h4-11H,1-3H3,(H2,22,23,24,25)

Chave InChI: XLOGLWKOHPIJLV-UHFFFAOYSA-N

SMILES: CC(C)(C)S(=O)(=O)C1=CC2=C(C=CN=C2C=C1)NC3=NNC4=C3C=C(C=C4)F

GSK583

CAS: 1346547-00-9

GSK583

Fórmula: C₂₀H₁₉FN₄O₂S

Pureza: 99.5%

Peso molecular: 398.45

Ref: 54-BUP06993

6-​[(1,​1-​Dimethylethyl)​sulfonyl]​-​N-​(5-​fluoro-​1H-​indazol-​3-​yl)​-4-​quinolinamine

CAS: 1346547-00-9

Fórmula: C₂₀H₁₉FN₄O₂S

Pureza: 98%

Cor e Forma: Solid

Peso molecular: 398.4539

Ref: IN-DA009CN1

GSK583

CAS: 1346547-00-9

6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine

Fórmula: C₂₀H₁₉FN₄O₂S

Pureza: 98%

Peso molecular: 398.45

Ref: IN-DG630156

GSK583

CAS: 1346547-00-9

GSK583 is a highly effective and specific RIP2 kinase inhibitor (IC50: 5 nM).

Fórmula: C₂₀H₁₉FN₄O₂S

Pureza: 98.68% - 99.81%

Cor e Forma: Solid

Peso molecular: 398.454

Ref: TM-T3537

GSK 583

CAS: 1346547-00-9

A potent and selective inhibitor of cell death-inducing kinase RIP2 (IC50 = 5 nM). Reduces release of pro-inflammatory cytokines. Inhibits production of TNF-α and IL-6 in intestinal explants from patients with Crohn's disease and ulcerative colitis.

Fórmula: C₂₀H₁₉FN₄O₂S

Pureza: Min. 95%

Cor e Forma: Powder

Peso molecular: 398.46 g/mol

Ref: 3D-BG163813

GSK583

CAS: 1346547-00-9

Pureza: 98%

Peso molecular: 398.121

Ref: 10-F870098